Serum leucine‐rich alpha‐2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy‐naïve cases with ulcerative colitis

Masashi Kono; Yoriaki Komeda; George Tribonias; Saki Yoshida; Kenji Nomura; Kohei Handa; Tomoyuki Nagai; Satoru Hagiwara; Shunsuke Omoto; Mamoru Takenaka; Naoshi Nishida; Naoko Tsuji; Hiroshi Kashida; Masatoshi Kudo

doi:10.1002/jgh3.12953

Back

Serum leucine‐rich alpha‐2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy‐naïve cases with ulcerative colitis

Article 2023 en

Abstract

1 min read

LRG was found to be the easiest marker to monitor disease activity and mucosal inflammation in UC patients with biotherapy-naïve cases, with a performance equivalent to that of Geboes scores.

Related publications

Article2017

Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis

Núria Planell, Maria Carme Masamunt, Raquel Franco Leal, Lorena Rodríguez, Manel Esteller, Juan José Lozano, Anna Ramírez, Maria de Lourdes Setsuko Ayrizono, Cláudio Saddy Rodrigues Coy, Ignacio Alfaro, Íngrid Ordás, Sudha Visvanathan, Elena Ricart, Jordi Guardiola, Julián Panés, Azucena Salas

Article2019

P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study

Andrés Yarur, Gerassimos J. Mantzaris, Mark S. Silverberg, Margaret Walshe, Petros Zezos, Dan Joseph Stein, M Bassel, T Lissoos, Claudia Lopez, Athanasios Natsios, Gabriela Radulescu, Haridarshan Patel, Dirk Demuth, Brian Bressler

Article2018

P546 Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim results

Brian Bressler, A. Greenup, M Bassel, Dan Joseph Stein, Manmohan Soni, Gabriela Radulescu, Calum S. Neish, J M Khalid, Dirk Demuth

Article2018

Baseline Ulcerative Colitis Endoscopic Index of Severity and Endoscopic Mayo Score Perform Similarly Predicting Response to Medical Therapy in Patients with Ulcerative Colitis

Hasan Bader, Lawrence Seymour, John Grady, Dan Joseph Stein, Andrés Yarur

Article2025

S1P Receptor Modulators Improve Clinical Outcomes in Ulcerative Colitis

Lokman Hekim Tanrıverdi, Feyzullah Aksan, Olga C. Aroniadis, Farah Monzur

Serum leucine‐rich alpha‐2 glycoprotein in monitoring disease activity and intestinal mucosal healing for biotherapy‐naïve cases with ulcerative colitis

Abstract

Discussion(0)

Related publications

Usefulness of Transcriptional Blood Biomarkers as a Non-invasive Surrogate Marker of Mucosal Healing and Endoscopic Response in Ulcerative Colitis

P573 Real-world effectiveness and safety of vedolizumab and anti-TNF in biologic-naive ulcerative colitis patients: Results from the EVOLVE study

P546 Vedolizumab outcomes in real-world bio-naive ulcerative colitis and Crohn’s disease patients (EVOLVE) in Canada: Interim results

Baseline Ulcerative Colitis Endoscopic Index of Severity and Endoscopic Mayo Score Perform Similarly Predicting Response to Medical Therapy in Patients with Ulcerative Colitis

S1P Receptor Modulators Improve Clinical Outcomes in Ulcerative Colitis